Evaluation of Ambient Ozone Effect in Bean and Petunia at Two Different Sites under Natural Conditions: Impact on Antioxidant Enzymes and Stress Injury

Tropospheric ozone is a harmful air pollutant and greenhouse gas that adversely affects living organisms. The effect of long-term ozone stress on the activity of SOD, APX, and GuPX, as well as lipid peroxidation and membrane injury in bean and petunia growing at a city site and in a forest, characterised by different ozone concentrations, was examined. The experiments were conducted in three growing seasons with different tropospheric ozone concentrations and meteorological conditions. Plants’ exposition to increased ozone concentration resulted in enhanced activity of antioxidant enzymes, level of lipid peroxidation, and membrane injury. In all years, higher ozone levels and solar radiation were observed at the forest site. The pattern of the changes in enzyme activity was dependent on ozone concentrations as well as on environmental conditions and varied from year to year. In the second year with the highest ozone concentration, the activity of GuPX and SOD increased the most. However, despite higher ozone concentration in the forest, a larger increase in APX and SOD activity in both species and GuPX activity in bean was recorded at the city site. The present results revealed that plant response to ozone might vary in different locations not only due to differences in ozone concentration but also because of the impact of other environmental factors, such as solar radiation and temperature

Does Potassium Modify the Response of Zinnia (<i>Zinnia elegans</i> Jacq.) to Long-Term Salinity?

Salinity is one of the major abiotic stress factors hindering crop production, including ornamental flowering plants. The present study examined the response to salt stress of Zinnia elegans ‘Lilliput’ supplemented with basic (150 mg·dm−3) and enhanced (300 mg·dm−3) potassium doses. Stress was imposed by adding 0.96 and 1.98 g of NaCl per dm−3 of the substrate. The substrate’s electrical conductivity was 1.1 and 2.3 dS·m−1 for lower potassium levels and 1.2 and 2.4 dS·m−1 for higher potassium levels. Salt stress caused a significant and dose-dependent reduction in leaf RWC, increased foliar Na and Cl concentrations, and reduced K. About 15% and 25% of cell membrane injury at lower and higher NaCl doses, respectively, were accompanied by only slight chlorophyll reduction. Salt stress-induced proline increase was accompanied by increased P5CS activity and decreased PDH activity. More than a 25% reduction in most growth parameters at EC 1.1–1.2 dS·m−1 but only a slight decrease in chlorophyll and a 25% reduction in the decorative value (number of flowers produced, flower diameter) only at EC 2.3–2.4 dS·m−1 were found. Salt stress-induced leaf area reduction was accompanied by increased cell wall lignification. An enhanced potassium dose caused a reduction in leaf Na and Cl concentrations and a slight increase in K. It was also effective in membrane injury reduction and proline accumulation. Increasing the dose of potassium did not improve growth and flowering parameters but affected the lignification of the leaf cell walls, which may have resulted in growth retardation. Zinnia elegans ‘Lilliput’ may be considered sensitive to long-term salt stress

Advances in the first line treatment of pediatric acute myeloid leukemia in the Polish Pediatric Leukemia and Lymphoma Study Group from 1983 to 2019

SIMPLE SUMMARY: We retrospectively analyzed the results of the five consecutive treatment protocols for pediatric acute myeloid leukemia (AML) used in Poland from 1983 to 2019 (excluding promyelocytic, secondary, biphenotypic, and Down syndrome AML). The study included 899 children. The probability of three-year overall, event-free, and relapse-free survival increased from 0.34 ± 0.03 to 0.75 ± 0.05, 0.31 ± 0.03 to 0.67 ± 0.05, and 0.52 ± 0.03 to 0.78 ± 0.05, respectively. A systematic reduction of early deaths and deaths in remission was achieved, while the percentage of relapses decreased only in the last therapeutic period. Surprisingly good results were obtained in the group of patients with unfavorable genetic abnormalities like KMT2A-MLLT10/t(10;11)(p12;q23) and DEK-NUP214/t(6;9)(p23;q24) who were treated in the AML-BFM 2012 Registry, while an unsatisfactory outcome was found in patients with FLT3-ITD. The use of standardized therapeutic protocols with the successive consideration of genetic prognostic factors and advances in supportive care led to a significant improvement in AML treatment outcomes over the last 40 years. ABSTRACT: Background: From 1983, standardized therapeutic protocols for pediatric acute myeloid leukemia (AML) based on the BFM group experience were introduced in Poland. We retrospectively analyzed the results of pediatric AML treatment in Poland from 1983 to 2019 (excluding promyelocytic, therapy-related, biphenotypic, and Down syndrome AML). Methods: The study included 899 children suffering from AML treated with the following: AML-PPPLBC 83 (1983–1993, n = 187), AML-PPGLBC 94 (1994–1997, n = 74), AML-PPGLBC 98 (1998–2004, n = 151), AML-BFM 2004 Interim (2004–2015, n = 356), and AML-BFM 2012 (2015–2019, n = 131). Results: The probability of three-year overall survival was 0.34 ± 0.03, 0.37 ± 0.05, 0.54 ± 0.04, 0.67 ± 0.03, and 0.75 ± 0.05; event-free survival was 0.31 ± 0.03, 0.34 ± 0.05, 0.44 ± 0.04, 0.53 ± 0.03, and 0.67 ± 0.05; and relapse-free survival was 0.52 ± 0.03, 0.65 ± 0.05, 0.58 ± 0.04, 0.66 ± 0.03, and 0.78 ± 0.05, respectively, in the subsequent periods. A systematic reduction of early deaths and deaths in remission was achieved, while the percentage of relapses decreased only in the last therapeutic period. Surprisingly good results were obtained in the group of patients treated with AML-BFM 2012 with unfavorable genetic abnormalities like KMT2A-MLLT10/t(10;11)(p12;q23) and DEK-NUP214/t(6;9)(p23;q24), while unsatisfactory outcomes were found in the patients with FLT3-ITD. Conclusions: The use of standardized, systematically modified therapeutic protocols, with the successive consideration of genetic prognostic factors, and advances in supportive care led to a significant improvement in AML treatment outcomes over the last 40 years

Pediatric acute myeloid leukemia post cytotoxic therapy-retrospective analysis of the patients treated in Poland from 2005 to 2022

Acute P./myeloid leukemia post cytotoxic therapy (AML-pCT) is rare complication of cancer treatment in childhood. The objective of the study was to identify clinical characteristics and provide an analysis of the outcomes in pediatric AML-pCT. We retrospectively analyzed the data of 40 children with AML-pCT, treated from 2005 to 2020 within the Polish Pediatric Leukemia and Lymphoma Study Group. The most common primary malignancies were acute lymphoblastic leukemia (32.5%) and brain tumors (20%). The median latency period was 2.9 years (range: 0.7–12.9). Probabilities of overall (OS), event-free (EFS), and relapse-free survival (RFS) in the whole cohort were 0.49 ± 0.08, 0.43 ± 0.08, and 0.64 ± 0.10, respectively. Significant improvements in outcomes were observed in patients treated from 2015–2022 (two induction cycles followed by stem cell transplantation—SCT in 69% of patients) compared to 2005–2014 (four induction cycles followed by SCT in 49% of patients). The probability of EFS increased from 0.30 ± 0.10 to 0.67 ± 0.12 (p = 0.07) and RFS increased from 0.46 ± 0.11 to 1.0 (p = 0.01). The poorest outcome (OS and EFS 0.25 ± 0.20) was in AML post brain tumor, mainly due to deaths from toxicities. To conclude, treatment results achieved in patients with AML-pCT treated from 2015–2022, with two induction cycles followed by immediate SCT, were better than those reported by other authors, and comparable to the results in de novo AML

Characteristics and Outcome of FLT3-ITD-Positive Pediatric Acute Myeloid Leukemia—Experience of Polish Pediatric Leukemia and Lymphoma Study Group from 2005 to 2022

Background: The FMS-like tyrosine kinase 3 (FLT3) gene mutated in 10–15% of pediatric acute myeloid leukemia (AML) is associated with an inferior outcome. The aim of the study was to analyze the outcome and characteristics of FLT3-ITD-positive pediatric AML. Methods: We retrospectively analyzed the nationwide pediatric AML database from between 2005 and 2022. FLT3-ITD was found in 54/497 (10.7%) patients with available analysis. Three consecutive treatment protocols were used (AML-BFM 2004 Interim, AML-BFM 2012 Registry, AML-BFM 2019 recommendations). Results: Probabilities of 5-year overall (OS), event-free (EFS) and relapse-free survival were significantly lower in the FLT3-ITD-positive patients compared to FLT3-ITD-negative (0.54 vs. 0.71, p = 0.041; 0.36 vs. 0.59, p = 0.0004; 0.47 vs. 0.70, p = 0.0029, accordingly). An improvement in the outcome was found in the analyzed period of time, with a trend of better survival in patients treated under the AML-BFM 2012 and AML-BFM 2019 protocols compared to the AML-BFM 2004 protocol (5-year EFS 0.52 vs. 0.27, p = 0.069). There was a trend of improved outcomes in patients treated with FLT3 inhibitors (n = 9, 2-year EFS 0.67 vs. 0.33, p = 0.053) and those who received stem cell transplantation (SCT) (n = 26; 5-year EFS 0.70 vs. 0.27, p = 0.059). The co-occurrence of the WT1 mutation had a dismal impact on the prognosis (5-year EFS 0.23 vs. 0.69, p = 0.002), while the NPM1 mutation improved survival (5-year OS 1.0 vs. 0.44, p = 0.036). Conclusions: It seems that SCT and FLT3 inhibitors have a beneficial impact on the prognosis. Additional genetic alterations, like the WT1 and NPM1 mutations, significantly influence the outcome